Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546665 | 0.86 | POLB (0.56) | POLBL3MBTL1VNN1RAB9ADPP4 | |
| SCHEMBL27877522 | 0.85 | AKR1C3 (0.42) | AKR1C3POLBL3MBTL1VNN1NAMPT | |
| SCHEMBL12414827 | 0.83 | MAPT (0.48) | RAB9ANPC1 | |
| SCHEMBL12413681 | 0.83 | DPP4 (0.41) | POLBL3MBTL1DPP4 | |
| SCHEMBL12414318 | 0.83 | TP53 (0.55) | POLBTP53 | |
| SCHEMBL12413684 | 0.82 | XPNPEP1 (0.42) | POLBL3MBTL1DPP4 | |
| SCHEMBL22307435 | 0.81 | XPNPEP1 (0.39) | POLBL3MBTL1DPP4 | |
| SCHEMBL16160876 | 0.81 | POLB (0.42) | POLBL3MBTL1DPP4 | |
| SCHEMBL20016419 | 0.81 | POLB (0.42) | POLBL3MBTL1DPP4 | |
| SCHEMBL12304178 | 0.81 | POLB (0.63) | POLBL3MBTL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |